Single arm, open label, prospective, observational study of gefitinib treatment for locally advanced (stage IIIB) or IV (metastatic) or relapsed NSCLC patients.
Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be performed. The detection rates of EGFR mutation will be compared using paired samples.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced stage IIIB not suitable for curative therapy or stage IV (metastatic) disease or relapsed NSCLC
ECOG Performance status 0\~2.
Written Informed Consent
Female or male patients aged 18 years or over, eligible for treatment for NSCLC
You may not be if
Previous exposure to EGFR-TKI
Concomitant use of other anti-cancer drugs with EGFR-TKI
Patients without available Tumor DNA
As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
Pregnancy or breast-feeding women (women of child¬bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.